By otakuyassine3@gmail.com 
TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $64.22, but opened at $61.32. TransMedics Group shares last traded at $63.35, with a volume of 215,169 shares traded.
Wall Street Analyst Weigh In
A number of brokerages have commented on TMDX. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Baird R W raised TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research report on Tuesday. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.
View Our Latest Report on TransMedics Group
TransMedics Group Stock Down 7.4 %
The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a market cap of $2.04 billion, a PE ratio of 64.77 and a beta of 2.06. The company’s fifty day moving average is $91.40 and its 200-day moving average is $129.80.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter last year, the business earned ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% on a year-over-year basis. On average, analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.
Insider Transactions at TransMedics Group
In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This trade represents a 12.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,417 shares of company stock worth $2,240,738 in the last quarter. Company insiders own 7.00% of the company’s stock.
Institutional Investors Weigh In On TransMedics Group
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Amalgamated Bank grew its position in shares of TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC grew its holdings in TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after buying an additional 81 shares in the last quarter. Signaturefd LLC raised its position in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after buying an additional 186 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its position in shares of TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after acquiring an additional 219 shares during the last quarter. 99.67% of the stock is owned by institutional investors.
TransMedics Group Company Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
Receive News & Ratings for TransMedics Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TransMedics Group and related companies with MarketBeat.com’s FREE daily email newsletter.